Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Getting right level of leptin may help protect cardiovascular health

Getting right level of leptin may help protect cardiovascular health

FDA approves first vaginal ring contraceptive that can be used for one year

FDA approves first vaginal ring contraceptive that can be used for one year

New HIV prevention guidelines from Canada released

New HIV prevention guidelines from Canada released

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

Penn researchers pinpoint some effective HIV drugs in causing neuronal damage

Penn researchers pinpoint some effective HIV drugs in causing neuronal damage

Many Canadian territories restrict access to medications for treating hepatitis C, study finds

Many Canadian territories restrict access to medications for treating hepatitis C, study finds

Hitchhiking of drugs on incorrect targets can cause adverse side effects

Hitchhiking of drugs on incorrect targets can cause adverse side effects

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

New drug combination may reduce need for complex regimens to treat hepatitis C

New drug combination may reduce need for complex regimens to treat hepatitis C

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung